{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:33:13Z","timestamp":1772137993218,"version":"3.50.1"},"reference-count":154,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T00:00:00Z","timestamp":1575504000000},"content-version":"vor","delay-in-days":4296,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1093\/annonc\/mdm442","type":"journal-article","created":{"date-parts":[[2007,9,29]],"date-time":"2007-09-29T20:13:25Z","timestamp":1191096805000},"page":"420-432","source":"Crossref","is-referenced-by-count":376,"title":["Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel"],"prefix":"10.1016","volume":"19","author":[{"given":"M.","family":"Aapro","sequence":"first","affiliation":[]},{"given":"P.A.","family":"Abrahamsson","sequence":"additional","affiliation":[]},{"given":"J.J.","family":"Body","sequence":"additional","affiliation":[]},{"given":"R.E.","family":"Coleman","sequence":"additional","affiliation":[]},{"given":"R.","family":"Colomer","sequence":"additional","affiliation":[]},{"given":"L.","family":"Costa","sequence":"additional","affiliation":[]},{"given":"L.","family":"Crin\u00f2","sequence":"additional","affiliation":[]},{"given":"L.","family":"Dirix","sequence":"additional","affiliation":[]},{"given":"M.","family":"Gnant","sequence":"additional","affiliation":[]},{"given":"J.","family":"Gralow","sequence":"additional","affiliation":[]},{"given":"P.","family":"Hadji","sequence":"additional","affiliation":[]},{"given":"G.N.","family":"Hortobagyi","sequence":"additional","affiliation":[]},{"given":"W.","family":"Jonat","sequence":"additional","affiliation":[]},{"given":"A.","family":"Lipton","sequence":"additional","affiliation":[]},{"given":"A.","family":"Monnier","sequence":"additional","affiliation":[]},{"given":"A.H.G.","family":"Paterson","sequence":"additional","affiliation":[]},{"given":"R.","family":"Rizzoli","sequence":"additional","affiliation":[]},{"given":"F.","family":"Saad","sequence":"additional","affiliation":[]},{"given":"B.","family":"Th\u00fcrlimann","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdm442_bb0010","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/bcr414","article-title":"Development of bisphosphonates","volume":"4","author":"Fleisch","year":"2002","journal-title":"Breast Cancer Res"},{"key":"10.1093\/annonc\/mdm442_bb0015","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/BF02938617","article-title":"Use of intravenous bisphosphonates in osteoporosis","volume":"5","author":"Civitelli","year":"2007","journal-title":"Curr Osteoporos Rep"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdm442_bb0020","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.9-90004-3","article-title":"Bisphosphonates: preclinical review","volume":"9","author":"Green","year":"2004","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdm442_bb0025","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1006\/bbrc.1996.1113","article-title":"Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes","volume":"224","author":"Rogers","year":"1996","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1093\/annonc\/mdm442_bb0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdm442_bb0035","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1471-2407-6-60","article-title":"Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells","volume":"6","author":"Goffinet","year":"2006","journal-title":"BMC Cancer"},{"issue":"Suppl 4","key":"10.1093\/annonc\/mdm442_bb0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1634\/theoncologist.9-90004-14","article-title":"Bisphosphonates: clinical experience","volume":"9","author":"Coleman","year":"2004","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdm442_bb0045","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0050","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1002\/1097-0142(20000615)88:12+<3054::AID-CNCR23>3.0.CO;2-Z","article-title":"Current and future directions in medical therapy: hypercalcemia","volume":"88","author":"Body","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0055","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1053\/j.semnephrol.2003.08.015","article-title":"Hypercalcemia of malignancy","volume":"24","author":"Body","year":"2004","journal-title":"Semin Nephrol"},{"key":"10.1093\/annonc\/mdm442_bb0060","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.eururo.2004.08.016","article-title":"Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care","volume":"46","author":"Saad","year":"2004","journal-title":"Eur Urol"},{"key":"10.1093\/annonc\/mdm442_bb0065","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med Care"},{"key":"10.1093\/annonc\/mdm442_bb0070","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.bjc.6602551","article-title":"Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration","volume":"92","author":"Wardley","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0075","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000082923","article-title":"The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer","volume":"67","author":"Delea","year":"2004","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdm442_bb0080","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jpainsymman.2007.01.001","article-title":"Managing metastatic bone pain: the role of bisphosphonates","volume":"33","author":"Gralow","year":"2007","journal-title":"J Pain Symptom Manage"},{"key":"10.1093\/annonc\/mdm442_bb0085","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdl093","article-title":"Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases","volume":"17","author":"Botteman","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0090","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.clinthera.2005.08.006","article-title":"Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom","volume":"27","author":"De Cock","year":"2005","journal-title":"Clin Ther"},{"key":"10.1093\/annonc\/mdm442_bb0095","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1093\/annonc\/mdl351","article-title":"The cost-effectiveness of bisphosphonates in metastatic breast cancer: letter to the editor in response to Botteman et al. 2006","volume":"18","author":"Souberbielle","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0100","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0105","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1053\/j.seminoncol.2006.03.022","article-title":"Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update","volume":"33","author":"Brufsky","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0110","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0115","doi-asserted-by":"crossref","first-page":"6301s","DOI":"10.1158\/1078-0432.CCR-06-1211","article-title":"Oral bisphosphonates as adjuvant therapy for operable breast cancer","volume":"12","author":"Powles","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm442_bb0120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0093-7754(01)90237-4","article-title":"Bisphosphonates in the prevention of bone metastases: current evidence","volume":"28","author":"Diel","year":"2001","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0125","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","article-title":"Metastatic bone disease: clinical features, pathophysiology and treatment strategies","volume":"27","author":"Coleman","year":"2001","journal-title":"Cancer Treat Rev"},{"key":"10.1093\/annonc\/mdm442_bb0130","article-title":"Fractures negatively affect survival in patients with bone metastases from breast cancer","volume":"94","author":"Hei","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdm442_bb0135","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0140","series-title":"The Cochrane Library","first-page":"1","article-title":"Bisphosphonates for the relief of pain secondary to bone metastases (Cochrane Review)","author":"Wong","year":"2004"},{"key":"10.1093\/annonc\/mdm442_bb0145","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"key":"10.1093\/annonc\/mdm442_bb0150","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0155","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0160","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0165","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J Intern Med"},{"key":"10.1093\/annonc\/mdm442_bb0170","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0175","first-page":"701","article-title":"Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bull Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0180","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0185","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003474.pub2","article-title":"Bisphosphonates for breast cancer","author":"Pavlakis","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdm442_bb0195","doi-asserted-by":"crossref","first-page":"6258s","DOI":"10.1158\/1078-0432.CCR-06-0840","article-title":"Breast cancer: bisphosphonate therapy for metastatic bone disease","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm442_bb0200","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0205","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1093\/annonc\/mdm442_bb0210","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"7","key":"10.1093\/annonc\/mdm442_bb0215","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdm119","article-title":"Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases","volume":"18","author":"Body","year":"2007","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdm442_bb0220","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/8756-3282(91)90063-O","article-title":"Treatment of skeletal disease in breast cancer with clodronate","volume":"12","author":"Paterson","year":"1991","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdm442_bb0225","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD006250","article-title":"Bisphosphonates for advanced prostate cancer","author":"Yuen","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdm442_bb0230","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/BF02549644","article-title":"Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer","volume":"24","author":"Elomaa","year":"1992","journal-title":"Int Urol Nephrol"},{"key":"10.1093\/annonc\/mdm442_bb0235","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm442_bb0240","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0885-3924(97)00075-4","article-title":"A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain","volume":"13","author":"Ernst","year":"1997","journal-title":"J Pain Symptom Manage"},{"key":"10.1093\/annonc\/mdm442_bb0245","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0022-5347(17)40597-0","article-title":"Palliation of painful bone metastases from prostate cancer using sodium etidronate: results of a randomized, prospective, double-blind, placebo-controlled study","volume":"141","author":"Smith","year":"1989","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdm442_bb0250","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1093\/annonc\/mdm442_bb0255","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/j.seminoncol.2004.07.026","article-title":"Ibandronate in metastatic bone pain","volume":"31","author":"Heidenreich","year":"2004","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0260","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0265","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm442_bb0270","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3816\/CGC.2005.n.009","article-title":"Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer","volume":"4","author":"Saad","year":"2005","journal-title":"Clin Prostate Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0275","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm442_bb0280","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0285","series-title":"Zoledronic acid reduces skeletal morbidity regardless of previous skeletal events in men with prostate cancer and bone metastases [poster]","author":"Saad","year":"2006"},{"key":"10.1093\/annonc\/mdm442_bb0290","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eursup.2007.03.006","article-title":"Bisphosphonates can prevent skeletal complications of malignant bone disease from prostate cancer and renal cell carcinoma","volume":"6","author":"Saad","year":"2007","journal-title":"Eur Urol Suppl"},{"key":"10.1093\/annonc\/mdm442_bb0295","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0300","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0305","first-page":"379","article-title":"The skeletal metastatic complications of renal cell carcinoma","volume":"19","author":"Zekri","year":"2001","journal-title":"Int J Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdm442_bb0310","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1634\/theoncologist.10-90001-8","article-title":"Efficacy of ibandronate in metastatic bone disease: review of clinical data","volume":"10","author":"Bell","year":"2005","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdm442_bb0315","first-page":"213","article-title":"A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy","volume":"17","author":"Piga","year":"1998","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm442_bb0320","unstructured":"Summary of product characteristics (SmPC) Clodronate, Bonefos\u00ae. Swissmedic (50957, 50958). 2006. http:\/\/www.kompendium.ch\/Search.aspx?lang=de"},{"key":"10.1093\/annonc\/mdm442_bb0325","unstructured":"Summary of product characteristics (SmPC) Ibandronate, Bondronat\u00ae. Swissmedic (53626, 56360, 57424). 2007. http:\/\/www.kompendium.ch\/Search.aspx?lang=de"},{"key":"10.1093\/annonc\/mdm442_bb0330","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2005.12.019","article-title":"Improving compliance and persistence with bisphosphonate therapy for osteoporosis","volume":"119","author":"Emkey","year":"2006","journal-title":"Am J Med"},{"issue":"8","key":"10.1093\/annonc\/mdm442_bb0335","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1093\/annonc\/mdm442_bb0340","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1185\/030079906X154042","article-title":"Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate","volume":"22","author":"Gold","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1093\/annonc\/mdm442_bb0345","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1742-1241.2006.01059.x","article-title":"Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study","volume":"60","author":"Cooper","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1093\/annonc\/mdm442_bb0350","article-title":"Poor persistency with oral bisphosphonates in cancer patients with bone metastasis","author":"G\u00f6l","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0355","first-page":"18623","article-title":"Higher persistency with i.v. bisphosphonates in patients with bone metastasis","volume":"24","author":"Mangiapane","year":"2006","journal-title":"ASCO Meeting Abstracts"},{"key":"10.1093\/annonc\/mdm442_bb0360","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00520-004-0628-z","article-title":"Bisphosphonate infusions: patient preference, safety and clinic use","volume":"12","author":"Chern","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0365","unstructured":"Summary of product characteristics (SmPC) Zoledronic Acid, Zometa\u00ae. Swissmedic (56257). 2005. http:\/\/www.kompendium.ch\/Search.aspx?lang=de"},{"key":"10.1093\/annonc\/mdm442_bb0370","unstructured":"Summary of product characteristics (SmPC) Pamidronate, Aredia\u00ae. Swissmedic (52092). 2005. http:\/\/www.kompendium.ch\/Search.aspx?lang=de"},{"key":"10.1093\/annonc\/mdm442_bb0375","unstructured":"Bondronat (ibandronic acid), Summary of Product Characteristics, 5 (IA) (EU\/1\/96\/012\/004 and EU\/1\/96\/009-013)Welwyn Garden City, UKRoche Registration, Ltd. Updated on March 6, 2007 based on EMEA\/H\/C\/101\/IA\/043"},{"key":"10.1093\/annonc\/mdm442_bb0380","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s005200100292","article-title":"Bisphosphonates for cancer patients: why, how, and when?","volume":"10","author":"Body","year":"2002","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0385","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3816\/CLC.2004.n.030","article-title":"Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications","volume":"6","author":"Hirsh","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0390","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy","volume":"24","author":"Clemons","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0395","article-title":"A phase II trial evaluating the palliative benefit of second-line oral ibandronate in breast cancer patients with either a skeletal related event (SRE) or progressive bone metastases (BM) despite standard bisphosphonate (BP) therapy","author":"Clemons","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdm442_bb0400","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0405","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm442_bb0410","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","article-title":"Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer","volume":"12","author":"Cook","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdm442_bb0415","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ejca.2006.12.006","article-title":"International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients","volume":"43","author":"Body","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0420","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0425","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/10543409608835120","article-title":"Statistical issues in quality-of-life assessment","volume":"6","author":"Chow","year":"1996","journal-title":"J Biopharm Stat"},{"key":"10.1093\/annonc\/mdm442_bb0430","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.clon.2005.06.016","article-title":"Quality of life and symptom end points in palliative bone metastases trials","volume":"18","author":"Chow","year":"2006","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1093\/annonc\/mdm442_bb0435","first-page":"S26","article-title":"Early phase in the development of a bone metastases quality of life module","volume":"19","author":"Chow","year":"2007","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1093\/annonc\/mdm442_bb0440","unstructured":"WHO's pain relief ladder http:\/\/www.who.int\/cancer\/palliative\/painladder\/en\/"},{"key":"10.1093\/annonc\/mdm442_bb0445","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s005200050213","article-title":"Bisphosphonates for metastatic bone pain","volume":"7","author":"Body","year":"1999","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0450","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ijrobp.2006.08.022","article-title":"Combination ibandronate and radiotherapy for the treatment of bone metastases: clinical evaluation and radiologic assessment","volume":"67","author":"Vassiliou","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1093\/annonc\/mdm442_bb0455","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10585-007-9066-x","article-title":"A novel study investigating the therapeutic outcome of patients with lytic, mixed and sclerotic bone metastases treated with combined radiotherapy and ibandronate","volume":"24","author":"Vassiliou","year":"2007","journal-title":"Clin Exp Metastasis"},{"key":"10.1093\/annonc\/mdm442_bb0460","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00005392-200101000-00033","article-title":"The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer","volume":"165","author":"Heidenreich","year":"2001","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdm442_bb0465","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.2004.07.054","article-title":"Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study","volume":"22","author":"Mancini","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0470","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubine","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm442_bb0475","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00001813-200502000-00001","article-title":"Ibandronate in metastatic bone disease: a review of preclinical data","volume":"16","author":"Bauss","year":"2005","journal-title":"Anticancer Drugs"},{"key":"10.1093\/annonc\/mdm442_bb0480","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1054\/bjoc.2001.1727","article-title":"The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel","volume":"84","author":"Jagdev","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0485","first-page":"432","article-title":"Additive\/synergistic anti-tumoral effects on prostate cancer cells in vitro following treatment with a combination of gemcitabine and zoledronic acid","volume":"22","author":"Ull\u00e9n","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0490","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000092489","article-title":"Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro","volume":"27","author":"Neville-Webbe","year":"2006","journal-title":"Tumour Biol"},{"key":"10.1093\/annonc\/mdm442_bb0495","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/ijc.20602","article-title":"Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells","volume":"113","author":"Neville-Webbe","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0500","first-page":"1109","article-title":"Breast tumour growth inhibition in vitro through the combination of cyclophosphamide\/metotrexate\/5-fluorouracil, epirubicin\/cyclophosphamide, epirubicin\/paclitaxel, and epirubicin\/docetaxel with the bisphosphonates ibandronate and zoledronic acid","volume":"12","author":"Vogt","year":"2004","journal-title":"Oncol Rep"},{"key":"10.1093\/annonc\/mdm442_bb0505","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s10585-006-9025-y","article-title":"Sequence- and concentration-dependent effects of acute and long-term exposure to the bisphosphonate ibandronate in combination with single and multiple fractions of ionising radiation doses in human breast cancer cell lines","volume":"23","author":"Journe","year":"2006","journal-title":"Clin Exp Metastasis"},{"key":"10.1093\/annonc\/mdm442_bb0510","doi-asserted-by":"crossref","first-page":"6737","DOI":"10.1200\/jco.2004.22.90140.6737","article-title":"Samarium-153Sm-EDTMP and zoledronic acid present synergistic action and are able to control pain and significantly improve QoL in elderly patients with MM. (Results of a phase II trial and 19 months follow up)","volume":"22","author":"Iuliano","year":"2004","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdm442_bb0515","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ncponc0688","article-title":"Therapy Insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease","volume":"4","author":"Dunstan","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0520","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"10.1093\/annonc\/mdm442_bb0525","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/BF02556671","article-title":"The acute-phase response after bisphosphonate administration","volume":"41","author":"Adami","year":"1987","journal-title":"Calcif Tissue Int"},{"key":"10.1093\/annonc\/mdm442_bb0530","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm442_bb0535","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002018-199921050-00004","article-title":"Comparative tolerability of drug therapies for hypercalcaemia of malignancy","volume":"21","author":"Zojer","year":"1999","journal-title":"Drug Saf"},{"key":"10.1093\/annonc\/mdm442_bb0540","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","article-title":"Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy","volume":"9","author":"Vogel","year":"2004","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdm442_bb0545","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00520-004-0655-9","article-title":"Rapid administration of ibandronate does not affect renal functioning: evidence from clinical studies in metastatic bone disease and hypercalcaemia of malignancy","volume":"12","author":"Pecherstorfer","year":"2004","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0550","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2165\/00044011-200626060-00002","article-title":"Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial","volume":"26","author":"Pecherstorfer","year":"2006","journal-title":"Clin Drug Investig"},{"issue":"18 Suppl","key":"10.1093\/annonc\/mdm442_bb0555","article-title":"Renal safety of intravenous ibandronate 6mg infused over 15 or 60 minutes in patients with breast cancer and bone metastases: a randomized, open-label study","volume":"25","author":"von Moos","year":"2007","journal-title":"ASCO Annual Meeting Proceedings Part I. J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0560","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1093\/annonc\/mdm442_bb0565","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/annonc\/mdl294","article-title":"Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy?","volume":"17","author":"Van den Wyngaert","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0570","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.tripleo.2006.06.004","article-title":"Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management","volume":"102","author":"Ruggiero","year":"2006","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1093\/annonc\/mdm442_bb0575","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jcms.2005.07.007","article-title":"Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?","volume":"33","author":"Lenz","year":"2005","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1093\/annonc\/mdm442_bb0580","first-page":"115","article-title":"Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient","volume":"20","author":"Koka","year":"2007","journal-title":"Int J Prosthodont"},{"key":"10.1093\/annonc\/mdm442_bb0585","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.critrevonc.2006.12.005","article-title":"Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients\u2014May 2006","volume":"62","author":"Weitzman","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdm442_bb0590","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0609.2007.00872.x","article-title":"Oral sodium clodronate induced osteonecrosis of the jaw in a patient with myeloma","volume":"79","author":"Montazeri","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdm442_bb0595","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates\u2014histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen","year":"2006","journal-title":"J Oral Pathol Med"},{"key":"10.1093\/annonc\/mdm442_bb0600","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw\u2014do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm442_bb0605","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2006.09.016","article-title":"Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis","volume":"40","author":"Zheng","year":"2007","journal-title":"Bone"},{"key":"10.1093\/annonc\/mdm442_bb0610","doi-asserted-by":"crossref","first-page":"602","DOI":"10.2106\/00004623-198466040-00016","article-title":"Effects of chemotherapeutic agents on bone. I. Short-term methotrexate and doxorubicin (adriamycin) treatment in a rat model","volume":"66","author":"Friedlaender","year":"1984","journal-title":"J Bone Joint Surg Am"},{"key":"10.1093\/annonc\/mdm442_bb0615","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0959-8049(97)10135-6","article-title":"Bone loss induced by cancer treatment and its management","volume":"34","author":"Delmas","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0620","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1200\/JCO.2000.18.7.1570","article-title":"Osteoporosis due to cancer treatment: pathogenesis and management","volume":"18","author":"Pfeilschifter","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0625","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1056\/NEJMoa052258","article-title":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer","volume":"353","author":"Thurlimann","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm442_bb0630","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(04)17666-6","article-title":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years\u2019 adjuvant treatment for breast cancer","volume":"365","author":"Howell","year":"2005","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdm442_bb0635","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1470-2045(07)70003-7","article-title":"Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study","volume":"8","author":"Coleman","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0640","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm442_bb0645","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1359\/jbmr.060508","article-title":"Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)","volume":"21","author":"Eastell","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdm442_bb0650","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1691::AID-CNCR21>3.0.CO;2-U","article-title":"Clodronate","volume":"80","author":"Kanis","year":"1997","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0655","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm442_bb0660","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group","volume":"339","author":"Cummings","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm442_bb0665","first-page":"651","article-title":"Osteoporosis in breast and prostate cancer survivors","volume":"19","author":"Hoff","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"10.1093\/annonc\/mdm442_bb0670","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0675","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.1997.15.3.955","article-title":"Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study","volume":"15","author":"Delmas","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0680","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdm442_bb0685","doi-asserted-by":"crossref","first-page":"416","DOI":"10.7326\/0003-4819-146-6-200703200-00006","article-title":"Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1093\/annonc\/mdm442_bb0690","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid effectively prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1093\/annonc\/mdm442_bb0695","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1200\/JCO.2005.05.3744","article-title":"Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer","volume":"25","author":"Brufsky","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdm442_bb0700","first-page":"S25","article-title":"An integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole","volume":"100","author":"Brufsky","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdm442_bb0705","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0710","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"10.1093\/annonc\/mdm442_bb0715","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2005.23.16_suppl.535","article-title":"Oral clodronate maintains bone mass in women with primary breast cancer","volume":"23","author":"McCloskey","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdm442_bb0720","first-page":"5","article-title":"Effects of oral clodronate (BONEFOS (R)) therapy on bone turnover and skeletal metastases in women with primary breast cancer","volume":"94","author":"McCloskey","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdm442_bb0725","article-title":"Effect of monthly oral ibandronate on anastrozole-induced bone loss during adjuvant treatment for breast cancer: One-year results from the ARIBON study","volume":"25","author":"Lester","year":"2007","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdm442_bb0730","doi-asserted-by":"crossref","unstructured":"M Aapro P Hadji A Brufsky. Recommendation for the prevention of Aromatase Inhibitor associated Bone Loss in women with Breast CancerSubmitted Poster Presentation, ECCO. 14, 2007","DOI":"10.1016\/S1359-6349(07)70769-3"},{"key":"10.1093\/annonc\/mdm442_bb0735","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdm442_bb0740","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0745","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"issue":"18 Suppl","key":"10.1093\/annonc\/mdm442_bb0750","article-title":"10-year follow-up of the efficacy of clodronate on bone mineral density (BMD) in early stage breast cancer","volume":"24","author":"Saarto","year":"2006","journal-title":"J Clin Oncol ASCO Annual Meeting Proceedings Part I"},{"key":"10.1093\/annonc\/mdm442_bb0755","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/jco.2004.22.90140.529","article-title":"Adjuvant clodronate treatment improves the overall survival of primary breast cancer patients with micrometastases to bone marrow\u2014a longtime follow-up","volume":"22","author":"Jaschke","year":"2004","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1093\/annonc\/mdm442_bb0760","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/sj.bjc.6603661","article-title":"Meta-analysis of clodronate and breast cancer survival","volume":"96","author":"Ha","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdm442_bb0765","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1385\/MO:22:2:195","article-title":"Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline","volume":"22","author":"Mystakidou","year":"2005","journal-title":"Med Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdm442_bb0770","first-page":"843","article-title":"Effect of zoledronate on persisting isolated tumor cells (ITC) in the bone marrow (BM) of patients without recurrence of early breast cancer","volume":"23","author":"Rack","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdm442_bb0775","unstructured":"R Coleman H Thorpe D Cameron. Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy\u2014first safety data from the AZURE trial (BIG01\/04) [poster] Presented at: 29th Annual San Antonio Breast Cancer Symposium; San Antonio, TX; December 14\u201317, 2006 (Abstr 2080)"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419411642?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419411642?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/19\/3\/420\/681184\/mdm442.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T16:43:17Z","timestamp":1629823397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419411642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":154,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0923753419411642"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdm442","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1120138.576284","asserted-by":"object"}]},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}